An interferon- and ribavirin-free dual combination of Bristol-Myers Squibb's hepatitis C virus (HCV) NS5A inhibitor daclatasvir (Daklinza) and HCV protease inhibitor asunaprevir (Sunvepra) produced sustained response in more than 90% of genotype 1b chronic hepatitis C patients in China, researchers reported at the 25th Conference or the Asian Pacific Association for the Study of the Liver this week in Tokyo.
